Endocrine therapy of advanced breast cancer

Acta Oncologica

Volumn 27, Issue 6, 1988, Pages 721-728

  Rose, C ^a,b,c   Mouridsen, H T ^a,b,c  

^a Department of Oncology R ^*  (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c FINSEN LABORATORY   (Denmark)

Author keywords

Advanced breast cancer; Endocrine therapy; Review of trials

Indexed keywords

AMINOGLUTETHIMIDE; DIETHYLSTILBESTROL; ETHINYLESTRADIOL; FLUOXYMESTERONE; GESTAGEN; HYDROCORTISONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NANDROLONE; PREDNISOLONE; TAMOXIFEN;

ADULT; AGED; BREAST CARCINOMA; DRUG THERAPY; FEMALE; HORMONAL THERAPY; HUMAN; METHODOLOGY; ORAL DRUG ADMINISTRATION; OVARIECTOMY; PRIORITY JOURNAL; REVIEW; SHORT SURVEY;

ADRENALECTOMY; AMINOGLUTETHIMIDE; BREAST NEOPLASMS; CLINICAL TRIALS; ESTROGENS; FEMALE; HORMONES; HUMAN; MENOPAUSE; OVARIECTOMY; PROGESTATIONAL HORMONES; RANDOM ALLOCATION; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0024235959     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841868809091775     Document Type: Article

References (50)

1. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination
2. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer
3. Hormontherapy of advanced breast carcinoma. Comparative evaluation of tamoxifen citrate versus medroxyprogesterone acetate
4. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer
5. Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer. Report of the Swiss Group for Clinical Cancer Research
6. Megestrol acetate v tamoxifen in advanced breast cancer. Correlation of hormone receptors and response
7. Metastatic breast cancer. Ovarian ablation with lower half-body irradiation
8. MPA Breast-Cancer Italian Clinical Trial Group. A multicentre randomized clinical trial with medroxyprogesterone acetata (MPA) at two different dosage schedules versus tamoxifen (TMX) in advanced breast cancer
9. Breast cancer first line hormonotherapy. A multicenter randomized trial comparing TAM with MAP & their sequential administration
10. Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer. A Southeastern Cancer Study Group Trial
11. Nandrolone decanoate added to tamoxifen in the treatment of advanced breast cancer
12. Cancer of the breast. The past decade
13. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer
14. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer
15. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer
16. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer
17. Tamoxifen and nandrolone-decanoate in treatment of metastatic breast cancer. A randomized study. Proc 3rd EORTC Breast Cancer Conference
18. Massive estrogen administration in premenopausal women with metastatic breast cancer
19. Therapeutic castration for advanced breast cancer
20. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer
21. Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer
22. Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer
23. A randomized trial of tamoxifen versus tamoxifen with aminoglutethimide in postmenopausal women with advanced breast cancer
24. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients
25. Tamoxifen in advanced breast cancer
26. Therapeutic effect of tamoxifen alone versus tamoxifen in combination with gestagen and estrogen in advanced breast cancer
27. Megestrol acetate (M) vs. tamoxifen (T) in advanced breast cancer (ABC). A five years report
28. Clinical evaluation of tamoxifen in advanced breast cancer (primary and recurrent) —Double blind study
29. Tamoxifen (Nolvadex) versus adrenalectomy in metastatic breast cancer
30. Oral high dose medroxyprogesterone acetate versus tamoxifen in postmenopausal patients with advanced breast cancer
31. Metastatic breast cancer. Controlled trial studying the optimal timing of hormonotherapy combined with chemoterapy (Preliminary report)
32. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazole, used in combination or sequentially
33. A clinical trial to compare the use of tamoxifen vs. stilboestrol in the treatment of postmenopausal women with advanced breast cancer
34. Tamoxifen versus medroxyprogesterone acetate loading doses as a third-line therapy for pretreated progressive postmenopausal breast carcinoma
35. Combined endocrine treatment of post menopausal patients with advanced breast cancer
36. Treatment of advanced breast cancer with tamoxifen
37. Combined endocrine treatment of postmenopausal patients with advanced breast cancer
38. The contribution of prednisolone (P) to primary endocrine therapy (PET) in advanced breast cancer
39. Medical adrenalectomy for treatment of metastatic breast carcinoma
40. Medroxyprogesterone acetate versus tamoxifen in advanced breast cancer
41. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: A randomized cross-over trial
42. The tamoxifen trial—A double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer
43. Contribution of prednisolone to the primary endocrine treatment of advanced breast cancer
44. Aminoglutethimide in the treatment of advanced breast cancer
45. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women
46. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer
47. Randomized trial of tamoxifen (TAM) alone or combined with fluoxymesterone (FLU) in postmenopausal women with metastatic breast cancer
48. Oral high-dose medroxyprogesterone acetate versus tamoxifen
49. Chemotherapy versus chemotherapy plus hormontherapy in postmenopausal advanced breast cancer patients
50. A comparison of ‘nolvadex’ (tamoxifen) monotherapy with ‘nolvadex’ plus halotestin (fluoxymesterone) in the treatment of advanced breast cancer in postmenopausal women. Proc 14th Int. Cancer Congr. (Abstr. 4826). Budapest 1986. 51. Westerberg H.: Tamoxifen and fluoxymesterone in advanced breast cancer. A controlled clinical trial.x